<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084499</url>
  </required_header>
  <id_info>
    <org_study_id>YCD143</org_study_id>
    <nct_id>NCT01084499</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Letrozole 2.5 mg Tablets</brief_title>
  <official_title>Bioequivalence Study of YUHAN Letrozole 2.5 mg Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to determine the bioequivalence of letrozole 2.5 mg tablets
      after administration of single doses to normal healthy Korean subjects under fasted
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile</measure>
    <time_frame>Predose(0hr) and post dose 16 times</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Screening, Pre-dose and Post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RT Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st period: Reference drug
2nd period: Test drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TR Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st period: Test drug
2nd period: Reference drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1st period - Reference drug</intervention_name>
    <description>FEMARA Tab.[Letrozole 2.5mg] Novartis, Antineoplastics</description>
    <arm_group_label>RT Group</arm_group_label>
    <other_name>FEMARA Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1st period - Test drug</intervention_name>
    <description>FERATRA Tab.[Letrozole 2.5mg] Yuhan Corporation, Antineoplastics</description>
    <arm_group_label>TR Group</arm_group_label>
    <other_name>FERATRA Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2nd period - Reference drug</intervention_name>
    <description>FEMARA Tab.[Letrozole 2.5mg] Novartis, Antineoplastics</description>
    <arm_group_label>TR Group</arm_group_label>
    <other_name>FEMARA Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2nd period - Test drug</intervention_name>
    <description>FERATRA Tab.[Letrozole 2.5mg] Yuhan Corporation, Antineoplastics</description>
    <arm_group_label>RT Group</arm_group_label>
    <other_name>FERATRA Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers in the age between 19 to 55 years old

          -  Subjects were neither congenital nor chronic diseases.

          -  Subjects were selected after passing a clinical screening procedure that included a
             physical examination and laboratory tests.

          -  Availability of subject for the entire study period and willingness to adhere to
             protocol requirements, as evidenced by a signed Informed Consent Form.

        Exclusion Criteria:

          -  Any history of a clinical condition which might affect drug absorption, distribution,
             metabolism or excretion or might be risk factors, e.g. clinically significant disorder
             in heart, liver, respiratory system, liver, kidney, gastrointestinal system and CNS

          -  Had a history of myocardial infarction, stroke, hypertension, arrhythmia, coronary
             artery disease, disease of neuropsychiatry, gastrointestinal system surgery (excluding
             appendectomy, herniotomy)

          -  Current clinically significant disorder in history taking or physical examination

          -  Acute disease within 14 days preceding the first application of study medication

          -  Had an relevant allergic disease

          -  Had history of hypersensitivity to drugs or any food

          -  Positive for Hepatitis B antigen, Hepatitis C antibody, HIV antibody, or High Quality
             Syphilis Reagin Test

          -  Excessive caffeine, alcohol intake and smoker(caffeine&gt;5 units/day, alcohol&gt;3
             units/day(1 unit = pure alcohol 10ml), cigarettes&gt; 20 cigarettes /day)

          -  Subjects who excessive alcohol intake or drug which affect drug metabolism enzyme
             intake within 30 days preceding study

          -  History of drug abuse or positive for urinary testing of drugs abuse (amphetamine,
             barbiturates, cocaine, opioids, benzodiazepines etc.)

          -  Has donated whole blood within 60days or apheresis within 14days preceding the first
             application of study medication

          -  Received other investigational drug within 60days preceding the first application of
             study medication

          -  Taken any herbal medicine within 30days, prescription medication within 14 days or
             over-the-counter drug (except for vitamins, minerals) within 10days preceding the
             first application of study medication (might affect this study or safety of subjects
             as judged by the investigator)

          -  Subjects couldn't eat ASAN MEDICAL CENTER standard meal or were unsuitable for this
             study as judged by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-seok Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

